Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm
- Malignant Solid Neoplasm
- Solid Neoplasm
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Beginning 7 days prior to transplant, patients receive Nozin via nasal single-use popswabs or single-use cotton tipped applicators and swab the inside of their nose two times daily (BID) up to 100 days after transplant. ARM II: Patients receive...
OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Beginning 7 days prior to transplant, patients receive Nozin via nasal single-use popswabs or single-use cotton tipped applicators and swab the inside of their nose two times daily (BID) up to 100 days after transplant. ARM II: Patients receive standard of care. After completion of study, patients are followed up every week for 6 weeks and then every alternate week until day 100.
Tracking Information
- NCT #
- NCT04060849
- Collaborators
- National Cancer Institute (NCI)
- Global Life Technologies Corp.
- Investigators
- Principal Investigator: Steven Pergam Fred Hutch/University of Washington Cancer Consortium
Get Well Soon